The downgrade from Outperform to Neutral by Wedbush indicates a less optimistic outlook for Freeline Therapeutics. The lowered price target from $8 to $5 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock price in the short term.